Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge. Alkermes extended gains for a second day ...

Microdosing GLP-1 drugs is trending on social media and supported by some doctors, but experts warn the practice lacks a ...

The FDA approved a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight with weight-related ...

The release of Innogen's inaugural annual report following its Hong Kong listing serves not merely as a financial disclosure, but as a strategic milestone—offering investors and stakeholders critical ...

Keep in mind common side effects of GLP-1s–including nausea, decreased appetite, dehydration, and excessive fatigue–may ...

La última incursión de la NFL en el uso de árbitros sustitutos terminó en una vergüenza para la liga, cuando una decisión mal ...

If you’ve been struggling with unstable blood sugar, sudden energy crashes, or unexplained weight gain, Gluco6 might ...

Signaling is fundamental to how cells sense and respond to their environment—but in immune cells, those signals must be ...

Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as ...

GLP-1 RAs are associated with a reduced risk for worsening of anxiety and depression that co-occur with diabetes and obesity.

Green-lit within 50 days of filing, orforglipron marks the first approval of a new molecular entity under the FDA ...

Investigators studied GLP-1 receptor agonist use and renal and inflammatory outcomes among patients with systemic lupus erythematosus and type 2 diabetes mellitus.